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tha
MaEnd-stage renal disease (ESRD) is a growing global health problem with major health and economic implications.
Cardiovascular complication is the major cause of morbidity and mortality in this population. Clustering of tradi-
tional atherosclerotic risk factors, such as diabetes, systemic inﬂammation, and altered mineral metabolism, con-
tributes to enhanced systemic atherosclerosis in patients with ESRD. Prevalence of obstructive coronary artery
disease (CAD) on coronary angiography exceeds 50% in this population. Despite having extensive CAD and
vascular disease, patients with ESRD often do not present with classic symptoms because of impaired exercise
capacity and diabetes. Furthermore, clinical trial data are exceedingly lacking in this population, resulting in
considerable clinical equipoise regarding the optimal approach to the identiﬁcation and subsequent management
of CAD in these patients. Traditional clinical screening tools, including conventional risk prediction models, are
signiﬁcantly limited in their predictive accuracy for cardiovascular events in patients with ESRD. Noninvasive cardiac
stress imaging modalities, such as nuclear perfusion and echocardiography, have been shown to improve the
traditional clinical model in identifying the presence of CAD. Furthermore, they add incremental prognostic
information to angiographic data. Novel imaging techniques and biomarker assays hold signiﬁcant promise in
further improving the ability to identify and risk-stratify for CAD. This review focuses on the current understanding
of the clinical risk proﬁle of asymptomatic patients with ESRD with an emphasis on the strengths and limitations
of various noninvasive cardiovascular imaging modalities, including the role of novel methods in reﬁning risk
prediction. In addition, issues and challenges pertaining to the optimal timing of initial risk assessment
(“screening”) and possible repeat screening (“surveillance”) are addressed. We also summarize the current data on
the approach to the patient with ESRD being evaluated for transplantation in the context of recent guidelines and
position statements by various professional societies. (J Am Coll Cardiol Img 2014;7:715–28) © 2014 by the
American College of Cardiology Foundation.E nd-stage renal disease (ESRD) represents ad-vanced dysfunction of the glomerular ﬁlterapparatus (glomerular ﬁltration rate <15 ml/
min/1.73 m2), which being essentially irreversible,
warrants renal replacement (1). More than one-half
million patients in the United States have ESRD
according to 2010 data from the U.S. Renal Data
System, with an annual incidence of >100,000
new cases reported in 2008 (2). The estimated
annual economic cost of ESRD is approximately $47.5
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Patients with ESRD are 8 times more likely to die
compared with the general U.S. population (1), and
cardiovascular causes account for >40% of all deaths
(3). Atherosclerotic coronary artery disease (CAD) is a
large proportion of the cardiovascular disease spec-
trum in patients with ESRD, with the prevalence
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ABBR EV I A T I ON S
AND ACRONYMS
BMIPP = b-methyl iodophenyl-
pentadecanoic acid
CACS = coronary artery
calcium score
CAD = coronary artery disease
CKD = chronic kidney disease
CT = computed tomography
CTA = computed tomography
angiography
DSE = dobutamine stress
echocardiography
EAT = epicardial adipose tissue
ECG = electrocardiography
ESRD = end-stage renal
disease
LV = left ventricular
LVEF = left ventricular ejection
fraction
LVH = left ventricular
hypertrophy
MI = myocardial infarction
MPS = myocardial perfusion
single-photon emission
computed tomography
PET = positron emission
tomography
SPECT = single-photon
emission computed
tomography
WMA = wall motion
abnormality
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716subjects without ESRD. This high prevalence
of CAD can be partially explained on the basis
of the clustering of traditional atherosclerotic
risk factors in ESRD (1). Furthermore, pa-
tients with ESRD who have documented CAD
often are asymptomatic, likely because of the
presence of diabetic or uremic neuropathy or
impaired exercise capacity (4).SEE PAGE 729Patients with ESRD also have substantially
worse outcomes after a cardiac event. For
instance, as demonstrated in a landmark
study of more than 34,000 patients on dial-
ysis, the 1-, 2-, and 5-year survival rates of
patients with ESRD who have an acute
myocardial infarction (MI) were 41%, 27%,
and 11%, respectively (5). Data from the
GRACE (Global Registry of Acute Coronary
Events) showed that patients with ESRD had
3-fold higher in-hospital and long-term
mortality and MI compared with the popu-
lation not receiving dialysis (6). Renal
dysfunction also is a well-known prognostic
factor after coronary artery bypass grafting.
Patients with renal replacement therapy un-
dergoing coronary artery bypass grafting
have a high operative and long-termmortality
(7). Patients with ESRD form the highest-risk
group with adverse cardiac outcomes, and
CAD screening/risk stratiﬁcation thus as-
sumes paramount importance. However,traditional atherosclerotic risk factors, including dia-
betes, hypertension, and dyslipidemia, are signi-
ﬁcantlymore prevalent in patients with ESRD, but they
only partially explain the increased risk for CAD and
coronary events (8), thereby signiﬁcantly limiting the
predictive ability of traditional risk estimate tools.
Furthermore, the Framingham risk score, the most
well-validated CAD risk prediction tool, does not
incorporate renal function (9). Pooled analyses from
large epidemiologic studies have demonstrated poor
predictive accuracy of the Framingham risk model in
cardiovascular risk prediction in patients with chronic
kidney disease (CKD), underestimating risk by asmuch
as 50% (10).
SERUM BIOMARKERS FOR RISK ASSESSMENT
The limited predictive accuracy of traditional risk
prediction instruments in the population with renal
failure has led to an extensive search for “novel”
risk factors, including the role of various biomarkers
to help reﬁne risk assessment. These include markersof myocardial injury, systemic inﬂammation, endo-
thelial dysfunction, sympathetic overactivation,
oxidative stress, and vascular atherosclerosis. These
novel markers are signiﬁcantly more prevalent in
patients with ESRD, in whom they seem to have a
stronger association with cardiovascular events
compared with patients without ESRD (11).
Among the wide array of extensively studied bio-
markers, the cardiac troponin assay seems to be most
promising. Troponin T is an extremely sensitive in-
dicator of myocardial necrosis. A meta-analysis from
28 prospective studies involving approximately
4,000 patients with ESRD with no symptoms found
that a positive troponin T level (>0.1 ng/ml) was a
major predictor for increased all-cause mortality
(relative risk: 2.64) and cardiac death (relative risk:
2.55) when adjusted for age, diabetes, left ventricular
hypertrophy (LVH), and depressed left ventricular
(LV) function (12).
In a small study, positive troponin T in patients
with ESRD with no symptoms at the initiation of
dialytic therapy was found to predict coronary ste-
nosis on coronary angiography (sensitivity: 92%;
speciﬁcity: 64%; area under the curve: 0.77) (13).
Conversely, the association between troponin I and
outcomes was less clear because of varying assays
and cutoffs. The U.S. Food and Drug Administration
currently approves the measurement of troponin
T in patients with ESRD, which is supported by the
Kidney Disease Outcomes Quality Initiative, although
this is not formally recommended (14). A recent
statement by the American College of Cardiology
Foundation highlighted the utility of troponin for
prognostication in patients with ESRD but empha-
sized unresolved issues regarding its clinical utility in
guiding clinical practice (15).
Although biomarkers do predict events, they are
limited by their lack of speciﬁcity. The speciﬁcity of
troponin is limited because it is elevated in more than
one-third of patients with ESRD (likely related to
LVH, hypertension/hypotension, and silent ischemia).
Furthermore, in the presence of other promising
biomarkers, selecting the best 1 or combination
thereof for reﬁning risk prediction and integrating
into part of a systematic approach for the manage-
ment of patients with ESRD will require well-
designed prospective trials.
CHALLENGES OF CAD SCREENING IN
PATIENTS WITH ESRD AND CARDIAC
STRESS IMAGING
A large proportion of the population with ESRD
cannot exercise because of frequent noncardiac
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717comorbidities, thereby necessitating the use of
pharmacologic stress. Several cardiovascular abnor-
malities associated with ESRD could limit the
diagnostic and predictive accuracy of established
noninvasive cardiac stress imaging tools (16). Altered
endothelial function with impaired coronary ﬂow
reserve in the absence of epicardial stenosis is well
known in diabetic patients with ESRD and could
decrease the sensitivity of vasodilator stress testing
(17). The presence of severe LVH also could compro-
mise the sensitivity of myocardial perfusion single-
photon emission computed tomography (MPS) by
missing small and mild perfusion defects because of
the partial volume effect. Increased LV mass or
concentric remodeling also limits the diagnostic
sensitivity of dobutamine stress echocardiography
(DSE) for subtle wall motion abnormality (WMA) (18).
In addition, increased afterload due to hypertensive
response could cause transient cavity dilation, ﬂat
inotropic response, and WMA in the absence of un-
derlying epicardial CAD. Yet, invasive and noninva-
sive angiographic evaluations of epicardial stenosis
are known to be limited in assessing the functional
signiﬁcance of noncritical coronary stenosis or
microvascular function (19).
One-quarter of all deaths in the population with
ESRD is thought to be due to sudden cardiac death
(20,21). A large proportion of patients with ESRDTABLE 1 MPS for Detection and Risk Stratiﬁcation of CAD in Patients
First Author,
Year (Ref. #) Modality N
Age,
yrs
Male,
%
DM,
% C
Kim et al.,
2004 (28)
Thallium;
dipyridamole
227 58.6 54 51
Hase et al.,
2004 (29)
Thallium; IV ATP 49 64 69 61
Momose et al.,
2009 (30)
Thallium; 14 exercise,
41 dipyridamole
55 55 70 90
Kim et al.,
2012 (31)
99mTc-tetrofosmin;
adenosine
215 57 52 57
ACM ¼ all-cause mortality; ACS ¼ acute coronary syndrome; ATP ¼ adenosine triphosph
DM ¼ diabetes mellitus; IV ¼ intravenous; MI ¼ myocardial infarction; MPS ¼ myocardiwith sickle cell disease do not have signiﬁcant
epicardial CAD. Factors such as microvascular dis-
ease, LVH, systolic dysfunction, autonomic insta-
bility, electrolyte, and volume shifts associated
with dialysis are potential contributors. Therefore,
screening for CAD would have only a modest impact
in this regard.
Despite these limitations, a large amount of data
have validated the effectiveness and clinical utility
of these noninvasive stress imaging techniques in
patients with ESRD. This is especially true in those
being evaluated for renal transplantation as part of
pre-operative risk assessment and to predict post-
renal transplant outcomes. Several regulatory bodies
and scientiﬁc councils have published guidelines for
the appropriate cardiac workup in patients with ESRD
who are awaiting renal transplantation. The approach
to patients with ESRD at the start of dialysis or for the
nontransplant candidate is less clear because of a less
robust body of evidence.
SCREENING AND RISK ASSESSMENT
IN PATIENTS NOT BEING EVALUATED
FOR TRANSPLANTATION
CORONARY ANGIOGRAPHY. The presence of epicar-
dial coronary stenosis (>50% or 70%) using invasive
angiography has been reported in 50% to 70% ofat the Initiation of Dialysis Therapy
Known
AD, %
Follow-Up
Duration, months
Type of
Events % Positive Scans Findings
13 34 ACM 22.5% with positive
thallium (reversible
and ﬁxed defects)
Age >60 yrs, DM, and CRP
>0.5 mg/dl had >40%
probability of positive
test results vs. 4% in the
absence of these
3 factors.
12 12 (median) MI, CD 27% reversible defects 96% event-free survival
for patients with normal
perfusion study results
at 1 yr
0 42 ACM, MI 22% reversible defects;
20% resting defect
Perfusion defect
independently associated
with death and MI.
Survival free of hard
events was 97.5% for
normal perfusion study
results at 3 yrs.
12 50 CD, ACS,
CHF
45% of patients had
perfusion defect
or SSS >4
Annual event rate: 15%
in the high-risk cohort
with abnormal MPS
ﬁndings, 4.5% in the
high-risk cohort with
normal MPS ﬁndings,
and 1.2% in the low-risk
cohort.
ate; CAD ¼ coronary artery disease; CD ¼ cardiac death; CHF ¼ congestive heart failure; CRP ¼ C-reactive protein;
al perfusion single-photon emission computed tomography; SSS ¼ summed stress score.
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718asymptomatic patients at the start of dialysis, with
multivessel involvement in 25% to 40% of studied
populations (22–24). Diabetes mellitus is a major
predictor of CAD. Because these studies are small and
selective, they likely overestimate the true burden of
disease. Regardless, the risk and cost of using inva-
sive angiography as a screening tool would be
prohibitive.
NUCLEAR IMAGING. Stress MPS imaging. MPS has
been well validated as a powerful prognostic tool in
patients with CKD (25–27). Less data exist for patients
at the initiation of dialysis therapy (28–31). A sum-
mary of these is provided in Table 1.
One prospective study assigned 215 asymptomatic
patients at the start of dialysis into low- and high-
risk groups using clinical and echocardiographicFIGURE 1 Incremental Prognostic Value of MPS Over Baseline (Clini
(Top) Global chi-square. (Bottom) Receiver-operating characteristic curv
under the curve; Echo ¼ echocardiography; MPS ¼ myocardial perfusion
photon emission computed tomography; 2D ¼ 2-dimensional.parameters (31). High-risk subjects then underwent
screening MPS. With an average follow-up of 4 years,
the annualized rate of adverse cardiac events was 15%
in the high-risk patients with abnormal MPS ﬁndings,
4.5% in the high-risk patients with normal MPS ﬁnd-
ings, and 1.2% in the low-risk patients. Diabetes,
perfusion defect, and left ventricular ejection fraction
(LVEF) were independent predictors of adverse out-
comes. An abnormal MPS ﬁnding carried a relative
risk of 3.3 compared with patients with normal re-
sults. Furthermore, MPS data added incremental
value to the baseline clinical/echocardiographic
model (Fig. 1). However, because of the size limita-
tion, no ﬁrm conclusions can be drawn in terms
of potential clinical/therapeutic implications of dif-
ferent risk categories based on the size, type, andcal Only) and Baseline Plus 2D Echocardiographic Variables
e analysis. Adapted with permission from Kim et al. (31). AUC ¼ area
single-photon emission computed tomography; SPECT ¼ single-
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719location of the perfusion abnormality. Nevertheless,
these studies show that there is a high prevalence
of perfusion defects (25% to 45%) and that the pres-
ence of perfusion defects, especially ischemia, is a
strong predictor of cardiac outcomes. Therefore,
they provide a solid base for using MPS to identify
high-risk populations at the start of dialysis. The
systematic approach of initial stratiﬁcation using
clinical and echocardiographic information could be
cost-effective. Asymptomatic patients without LV
dysfunction, risk factors, or long-standing diabetes
are at relatively low risk and would not beneﬁt from
further stress testing (32). However, the risk of those
with “high clinical echocardiographic risk” can be
further reﬁned by using stress MPS imaging (31).
Similar ﬁndings were observed in a study of
121 patients already receiving chronic maintenance
dialysis. Abnormal MPS ﬁndings and depressed
LVEF were both strong independent predictors of
outcomes. Patients with a high summed stress score
and summed difference score ($4) had a >5 times
higher risk of cardiac death (33).
Cardiac fatty acid metabolism radionuclide imaging. The
major source of energy for the normal myocardium is
through myocardial fatty acid metabolism. Under
conditions of myocardial ischemia, there is a switch
from fatty acid metabolism to glucose as a primary
source of energy. This change can be detected using
fatty acid radiotracers, such as b-methyl iodophenyl-
pentadecanoic acid (BMIPP). The impaired use by
beta-oxidation leads to longer presence inside the
cardiac myocytes, allowing it to be imaged (34). The
imaging of this altered myocardial BMIPP metabolismFIGURE 2 Role of Myocardial Fatty Acid Metabolism Imaging in ESR
(Left) b-methyl iodophenyl-pentadecanoic acid (BMIPP) and Tl myocardi
images from 3 patients who died from cardiac events. (Right) Event-free
scores of $7 and #6, respectively. Log-rank test: p < 0.0001. Adapted
disease.at rest indicating changes triggered by the preceding
ischemia has been termed “ischemic memory imag-
ing.” Nishimura et al. (35) investigated the prevalence
of CAD in patients on dialysis who underwent dual
isotope thallium-201 and BMIPP single-photon emis-
sion computed tomography (SPECT) at rest followed
by coronary angiography. An abnormal scan ﬁnding
(BMIPP summed score of >6) predicted obstructive
CAD with good diagnostic accuracy (sensitivity,
speciﬁcity, and accuracy were 98%, 66%, and 90%,
respectively.) The same authors also demonstrated
the prognostic utility of dual isotope thallium-201
and BMIPP SPECT in 375 asymptomatic patients on
dialysis with no history of CAD (36). After >3 years of
follow-up, BMIPP summed scores $12 carried a >2-
fold risk for cardiac death. Furthermore, BMIPP-
thallium-201 mismatch (an indicator of ischemia)
further reﬁned risk stratiﬁcation such that the cardiac
death-free survival of patients with a mismatch
score <7 was 96% as opposed to 53% in patients with
a score >7 (Fig. 2). The results of this study show the
potential of BMIPP SPECT in predicting cardiac death
in asymptomatic patients on dialysis who do not have
a history of CAD or MI. However, BMIPP is not yet
approved in the United States.
Coronary ﬂow reserve assessment with positron emission
tomography. In patients with renal dysfunction, the
severity of coronary vascular dysfunction, as
assessed by positron emission tomography (PET), is a
strong predictor of cardiac death. Murthy et al. (37)
recently evaluated this hypothesis in 866 patients
who underwent predominantly vasodilator stress
PET imaging with rubidium-82 (17% ESRD) and wereD
al perfusion single-photon emission computed tomography mismatch
survival curves for cardiac death for patients with BMIPP/Tl mismatch
with permission from Nishimura et al. (35). ESRD ¼ end-stage renal
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720followed for approximately 1 year. Those with
abnormal coronary ﬂow reserve (failure of myocar-
dial blood ﬂow to increase adequately on demand)
had a signiﬁcantly higher rate of cardiac mortality
(10.7% vs. 3.2%/year in those with relatively pre-
served coronary vasodilator reserve, p < 0.0001).
Identiﬁcation of coronary vasodilator dysfunction
improved risk stratiﬁcation beyond comprehensive
clinical assessment, LV systolic function, and semi-
quantitative measures of myocardial ischemia and
scar. A moderate net reclassiﬁcation was seen after
incorporating coronary ﬂow reserve information,
which was most notable in the intermediate-risk
group (2% to 4% annualized of cardiac death). It
appropriately downgraded 21% of them to low risk
(0% annualized cardiac mortality) and upgraded 15%
of them to high risk (9.8% annualized cardiac mor-
tality) (37).
Therefore, the potential role of coronary ﬂow
reserve quantiﬁcation may reside in risk-stratifying
patients without overt regional perfusion defects
with other imaging modalities and could be used to
test medical therapy that could improve vasomotor
function.
ECHOCARD IOGRAPHY- BA S ED AS S E S SMENT.
Dobutamine stress echocardiography. Multiple studies
using DSE have demonstrated its incremental prog-
nostic utility over clinical data for demonstrating
resting and stress-induced regional WMA. In 485
patients with CKD (one-half were on dialysis), a 25%
increase in the percentage of segments with induced
WMA by DSE was associated with higher all-cause
mortality (hazard ratio: 1.40) after a mean follow-up
period of 2.5 years (38). Similar results were demon-
strated by combining clinical and stress echocardi-
ography information (39). An abnormal DSE result
had a hazard ratio of 4.3 (95% conﬁdence interval:
1.8 to 10.0) for major cardiac events on multivar-
iable analysis. This study substantiated a 2-tiered
approach of initial stratiﬁcation based on clinical
variables followed by DSE for further risk reﬁnement.
DSE did not provide signiﬁcant risk reclassiﬁcation in
the low-risk group. However, it did provide effective
discrimination in the high-risk groups as deﬁned by
baseline clinical variables. These studies using DSE in
patients with ESRD further support the approach of
initial clinical risk factor evaluation to identify pa-
tients at risk who would be best discriminated by
stress imaging.
Myocardial contrast echocardiography. Perfusion defects
on rest myocardial contrast echocardiography
without a stress component have been reported to
have a modest positive predictive value and a highnegative predictive value for detection of obstructive
CAD (40). They also predicted cardiac death and
revascularization (41). However, the small sample
size together with the absence of stress imaging raises
questions regarding the applicability of these data.
The other major limitations of myocardial contrast
echocardiography are image quality standardization
and need of technical expertise to perform and
interpret the study.
CORONARY ARTERY CALCIUM MEASUREMENT/
HYBRID IMAGING. Large epidemiologic studies have
shown the correlation between a decrease in
glomerular ﬁltration rate and increased coronary ar-
tery calcium score (CACS) (42,43). When compared
with subjects not on dialysis, patients with ESRD
of different age groups and varying duration of dial-
ysis have been reported to have a 2 to 5 times higher
prevalence of coronary atherosclerosis as detected by
CACS (44–46). In addition, they have a more severe
burden of disease, because approximately 3 of 4
patients with ESRD had CACS >75th percentile for
sex- and age-matched subjects without ESRD (46).
Coronary calciﬁcation is often present and frequently
progresses even in young adults (age 20 to 29 years)
with ESRD who are receiving dialysis. The presence
of coronary artery calciﬁcation was found in 80% of
patients and among patients with calciﬁcation who
underwent follow-up computed tomography (CT).
CACS approximately doubled over a mean period
of 2 years (45).
The CACS in patients with ESRD is a combination
of calciﬁcation in the intima (related to ischemic
heart disease in the population without ESRD) and
the media (not present in patients without ESRD)
(47). This has been used as the explanation of
limited speciﬁcity in predicting stenotic disease in a
small study of 18 patients with ESRD (48). However,
a recent publication using coronary computed to-
mography angiography (CTA) for assessment of
coronary plaques showed that the calcium score
correlated well with plaque burden, and the diag-
nostic association between the calcium score and
the atherosclerotic lesions was good irrespective of
ESRD status (49).
In the general population, a calcium score of 0 is
rarely seen in patients with signiﬁcant coronary
stenosis. Absence of calcium has a high (>95%)
negative predictive value for signiﬁcant angiographic
coronary stenosis in symptomatic patients with a
high pre-test likelihood of CAD (50). Some data also
exist for CACS as a predictor of future cardiac events
in the population with ESRD (51–54) (Table 2). As in
the general population, CACS offered an incremental
TABLE 2 CACS as a Predictor of Future Cardiac Events or Mortality in the Population With ESRD
First Author,
Year (Ref. #) CT/Population
Age, yrs
(mean  SD)
Mean Duration
of ESRD
Follow-Up
Duration Finding
Matsuoka et al.,
2004 (52)
EBCT
104 patients
55.9  13.6 48.7 months 5 yrs Survival rate of 84.2% in the low CACS group and
67.9% in the high CACS group. The adjusted
RR for death was 1.001 (1.000–1.002);
p ¼ 0.0003, for the absolute value of CACS.
Shantouf et al.,
2010 (54)
EBCT
166 patients
53  13 64% on dialysis
for >2 yrs
6 yrs Adjusted risk of death compared with CACS 0:
HR: 8.5 (95% CI: 1.1–48.1, p ¼ 0.02) for
CACS 101–400 and HR: 13.3 (95% CI:
1.3–65.1, p ¼ 0.01) if CACS >400
Ohtake et al.,
2010 (51)
EBCT
74 patients
65.9  10.6 90 months 15 months CACS predicted cardiovascular events (and
all-cause deaths, p ¼ 0.026) with best
discriminatory cutoff value of CACS of 750.
Drozdz et al.,
2011 (53)
EBCT
64 patients
48.9 78 months 5 yrs CACS was an independent predictor of mortality
(OR: 1.82 for every 100 CACS).
CACS ¼ coronary artery calcium score; CI ¼ conﬁdence interval; CT ¼ computed tomography; EBCT ¼ electron-beam computed tomography; ESRD ¼ end-stage renal disease; HR ¼ hazard
ratio; OR ¼ odds ratio.
FIGURE 3 Role of CACS in ESRD
(A) A 42-year-old man with hypertension, dyslipidemia, obesity, and ESRD on
chronic dialysis for 36 months. The adenosine MPS result was normal with a
left ventricular ejection fraction (LVEF) of 56%. The coronary artery calcium
score (CACS) was zero. The patient was free of cardiovascular events at 4-year
follow-up. (B) A 39-year-old man with type II diabetes, obesity, and ESRD on
chronic dialysis for 19 months. The adenosine MPS result was normal with an
LVEF of 53%. The CACS was 1,137 with calciﬁcation noted in all 3 coronary
arteries ([left] left anterior descending coronary artery; [right] left circum-
ﬂex/obtuse marginal and right coronary artery). The patient presented 3 years
later with non–ST-segment elevation myocardial infarction with >70% ste-
nosis noted in the diagonal and obtuse marginal arteries on coronary angio-
gram. Abbreviations as in Figures 1 and 2.
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721predictive value to clinical risk factors. Overall, the
results of these studies support the notion that pa-
tients with ESRD have a higher burden of athero-
sclerosis and that CACS has a great potential for CAD
screening and risk stratiﬁcation.
In this context, there may be a role for hybrid
imaging, incorporating CACS along with other stress
modalities, to reﬁne the process for evaluation of
high-risk patients with ESRD (Fig. 3). The prevalence
of abnormal MPS ﬁndings and obstructive CAD in the
general population is directly related to the magni-
tude of CACS. In addition, CACS (especially when
severe) provides incremental prognostic information
to perfusion defects from MPS (55,56). The annual
overall cardiac event rate is approximately 3% in
those with normal MPS ﬁndings with an underlying
severe CACS compared with 0.7% in those with
CACS <10. However, the known excellent negative
predictive value of a CACS of 0 in excluding signiﬁ-
cant angiographic CAD or ischemia on functional
testing makes it an attractive tool in serving as a
gatekeeper for invasive angiography or stress testing
in asymptomatic patients without a history of CAD
(56).
This approach is supported by a recently published
study (57) that evaluated the role of hybrid imaging
(CACS, epicardial adipose tissue [EAT], volume, and
myocardial perfusion imaging) using SPECT-CT
(97.5%) or PET-CT (2.5%) in 411 patients with ESRD
(86% on dialysis) awaiting kidney transplant. Com-
pared with patients with no perfusion defect, pa-
tients with abnormal scan results had higher median
CACS (412 vs. 27.5) and EAT volumes (148.5 ml vs.
115.7 ml). Likewise, CACS and EAT were indepen-
dently associated with abnormal perfusion in multi-
variate logistic regression analysis. On the basis ofthese ﬁndings, the authors propose using CACS and
EAT as potential “ﬁlters” for downstream testing (57).
For a wider adoption of hybrid imaging in the pre-
renal transplant population, larger studies with hard
clinical endpoints are needed. In addition, the cost-
effectiveness of this approach along with establish-
ing optimal cutoff values for CACS and potentially
EAT as risk predictors will need to be studied sys-
tematically (58).
CORONARY CTA. Recent advances have made
possible the noninvasive assessment of CAD with
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722CTA. A multicenter study showed that CTA performed
well in detecting/excluding coronary stenosis when
compared with invasive angiography. Overall, the
positive predictive value was moderate, but the
negative predictive value was high (>98%) (59). In
addition to its diagnostic ability, a large amount of
outcome data have also validated its prognostic
value. In particular, those subjects with no evidence
of CAD on CTA had excellent short- to intermediate-
term prognosis (60).
Limited data exist evaluating the role of CTA in
patients with ESRD (61,62). One small study using a
16-slice multidetector CT system in 19 patients
showed that 14% of vessels could not be evaluated.
Compared with invasive angiography, the sensitivity,
speciﬁcity, and positive and negative predictive
values of CTA for a diagnosis of >50% stenosis were
86%, 81%, 78%, and 88%, respectively (61). Another
small study (N ¼ 29) using 64-slice CTA showed that
36% of patients with ESRD actually had a zero to low
CACS, making major obstructive CAD unlikely.
Although the overall correlation between high CACS
and obstructive disease was good, a signiﬁcant
number of patients with CACS between 400 and
2,000 had <70% stenosis, with many having <50%
disease by CTA in the major coronary arteries (62).
The main challenge of interpreting CTA in patients
with ESRD is to overcome the adverse effect of the
high calciﬁc burden seen in this population. In the
study by Mao et al. (62), 10% of the scans were
deemed uninterpretable.
Yet, a recent publication (63) lends support to the
potential role of CTA in patients with ESRD. In 70
patients with ESRD on long-term dialysis undergoing
CTA, the prevalence of signiﬁcant CAD (luminal
narrowing >50%) was 43%. More than 90% of the
segments were interpretable; 19 of the 54 uninter-
pretable segments were considered uninterpretable
because of extensive calciﬁcation. The remaining 35
segments were considered uninterpretable for tech-
nical reasons, including motion artifacts and poor
contrast arrival. After 2 years of follow-up, 36% of
those with CAD had a cardiac event compared with
none of the patients with no signiﬁcant CAD (p <
0.01) (63). Further studies using the newer genera-
tion of multidetector CT are needed to see whether
the new advances in CTA technologies (wide
coverage, dual-source/energy detectors, perfusion,
faster gantry, and new detector materials) can
improve the diagnostic performance in this chal-
lenging population. In view of the known excellent
negative predictive value of a CACS of 0 and
normal CTA results in excluding signiﬁcant angio-
graphic CAD, the potential role of CTA likely restsin serving as gatekeeper for invasive angiography
in those patients with submaximal, equivocal, or
mildly abnormal stress testing results.
CARD IAC MAGNET IC RESONANCE IMAG ING .
Myocardial scar pattern and burden on cardiac mag-
netic resonance (CMR) are well validated for risk
assessment of ischemic heart disease in the general
population. Such data do not exist in patients with
ESRD. The presence of subendocardial scar by de-
layed hyperenhancement CMR in a small number of
patients with ESRD has been related to CAD risk
factors, depressed LVEF, and severe CAD on angiog-
raphy (64). Unfortunately, the risk of gadolinium-
induced nephrogenic systemic ﬁbrosis in ESRD
precludes the use of CMR (65). A safer contrast agent,
such as ferumoxytol, has mainly intravascular distri-
bution after administration, so it does not seem to
have signiﬁcant potential for scar assessment in this
population (66).
SCREENING AND RISK STRATIFICATION
OF THE PATIENT WITH ESRD BEING
EVALUATED FOR TRANSPLANTATION
Patients being considered for renal transplantation
generally undergo comprehensive cardiac assess-
ment. Considering the limited organ availability and
the ever growing demand, such risk assessment could
help in determining transplant candidacy. In addi-
tion, CAD remains the major cause of death post-
renal transplantation, with approximately one-third
of all such deaths due to MI (67,68). Identifying pa-
tients who may beneﬁt from pre-operative coronary
revascularization might decrease perioperative and
post-transplant cardiac events (69).
Almost all pre-transplant evaluation studies
centered their efforts on identifying the presence of
epicardial coronary stenosis in pre-renal transplant
recipients using invasive coronary angiography or
noninvasive stress imaging, such as MPS or DSE.
Exercise electrocardiography (ECG) has been re-
ported to have a low sensitivity (32%) in detecting
CAD in this population (70). The often associated ECG
abnormality (e.g., LVH) and reduced exercise capac-
ity also make exercise ECG testing not suitable for
screening purposes.
I NVAS IVE CORONARY ANG IOGRAPHY. Angio-
graphic prevalence of CAD in patients undergoing
pre-transplant evaluation (>50% or 70% luminal ste-
nosis) ranged from 40% to 60%, with multivessel
involvement in 20% to 33% of the studied pop-
ulations (71–73). The presence of angiographic CAD
also predicted cardiovascular events in 106 patients
before renal transplantation. After 4 years, only 6%
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723of patients with <70% coronary artery stenosis had
a cardiac event compared with those with >70%
stenosis (71).
In a large study of 3,698 patients who were
referred for MPS as part of renal transplant evalua-
tion, signiﬁcant CAD (>50% stenosis) was found in
62% of 260 patients who underwent invasive angi-
ography (33% with 3-vessel disease). After a mean
follow-up of 30  15 months, depressed LVEF,
myocardial perfusion defects on MPS, diabetes, and
age >45 years were all predictors of worse outcome,
whereas degree of angiographic CAD was not. In
addition, revascularization improved survival only in
the subset of patients with 3-vessel disease without
previous coronary artery bypass graft surgery but not
in others (72). Similar results were reported in a
cohort of 222 patients (73). There was no apparent
survival difference between patients who underwent
angiography and patients who did not. Therefore, on
the basis of these ﬁndings, routine invasive angiog-
raphy before transplant is not recommended.
NONINVASIVE CARDIAC STRESS IMAGING. Several
studies examined the “diagnostic performance” of
MPS and DSE using coronary luminal stenosis on
invasive angiography as the endpoint (deﬁned as
luminal narrowing >50% in any epicardial vessel).
The sensitivity of MPS ranged from 29% to 100%, and
speciﬁcity ranged from 31% to 88% (74–77). Stress-
induced WMA on DSE had a sensitivity of 44% to
96% and a speciﬁcity of 60% to 100% (70,78–84) for
identifying luminal stenosis >50%. In addition to
challenges mentioned earlier, there are additional
reasons that could explain this wide range of diag-
nostic accuracy. Balanced ischemia can be missed by
MPS. The sample size of these studies was small, and
there is signiﬁcant veriﬁcation bias because only
positive studies undergo invasive angiographic cor-
relation. Most important, a luminal stenosis of 50%
or even 70% often can be physiologically and
hemodynamically insigniﬁcant (19,85). In the land-
mark FAME (FFR vs Angiography for Multivessel
Evaluation) trial, only 35% of stenosis in the 50%
to 70% range (cutoff used in most diagnostic accu-
racy studies for stress tests) was functionally
signiﬁcant (fractional ﬂow reserve <0.80) (85).
Whether this applies to patients with ESRD is not
clear. However, it would be reasonable to adapt the
well-accepted approach of using hard clinical end-
points as outcome measures for reﬂecting the pre-
dictive accuracy of stress imaging rather than using
anatomy as the endpoint. A large amount of data
amassed over the past 2 decades have ﬁrmly estab-
lished the prognostic value of both MPS and DSE inrisk stratiﬁcation of the pre-transplant patient
(74–84,86). A pooled analysis of 12 studies (8 using
thallium MPS and 4 using DSE) showed that the
presence of ischemia conferred a 6-fold risk of MI
and a 4-fold risk of cardiac death (87). Yet, the
presence of scar or ﬁxed defects only predicted car-
diac death (relative risk: 4.7) but not MI. Normal MPS
results conferred an event-free survival of 97.7% for
MI and 96.9% for cardiac death at 1 year (87). A more
recent study using MPS with technetium-99m also
conﬁrmed that the presence of reversible perfusion
defects on MPS had an adjusted hazard ratio of 1.92
(95% conﬁdence interval: 1.1 to 4.4) for mortality
(88). More important, the functional information
derived from MPS or DSE was a more powerful pre-
dictor of outcomes than the purely anatomic infor-
mation from angiography (72,89,90).
GUIDELINES
Several regulatory bodies and scientiﬁc councils,
including the recent American College of Cardiology
and American Heart Association guidelines, have
emerged to provide a framework for the appropriate
workup of the patient with ESRD awaiting renal
transplantation (91–95). A summary of these guide-
lines is provided in Table 3. The common theme in
the recommendations is against routine invasive
coronary angiography for CAD screening. Asymp-
tomatic patients with 3 or more risk factors (diabetes
mellitus, previous CAD, >1 year on hemodialysis,
LVH, age >60 years, smoking, hypertension, and
dyslipidemia) should receive a noninvasive stress
test regardless of functional status. Although none of
the guidelines specify which stress imaging modality
to use, the general opinion is that the modality with
the best local expertise and experience should be
used. In general, the indication for invasive coronary
angiography and revascularization should be similar
to that for the general population. Routine angiog-
raphy and then prophylactic coronary revasculariza-
tion before transplantation surgery in stable patients
without established indications to improve symptom
or survival are not recommended.
REPEAT OR SURVEILLANCE TESTING
In regard to the issue of repeat stress testing (sur-
veillance), there is no consensus between the
different guidelines (91–95). According to the 2012
American Heart Association/American College of
Cardiology document, the value of the practice to
reduce cardiac events in the pre-transplant popula-
tion is uncertain (94). On the contrary, the 2005
TABLE 3 Summary of Guidelines for the Appropriate Workup for the Patient
With ESRD Awaiting Renal Transplantation
Guideline (Ref. #) Recommendations
2012 ACC/AHA Scientiﬁc
Statement (94)
Noninvasive stress testing may be considered in those with
no active cardiac conditions: presence of multiple CAD risk
factors regardless of functional status (Class IIb, Level of
Evidence: C).
Relevant risk factors include diabetes mellitus, prior
cardiovascular disease, >1 yr on dialysis, LV hypertrophy,
age >60 yrs, smoking, hypertension, and dyslipidemia;
the speciﬁc number of risk factors that should be used
to prompt testing remains to be determined, but the
committee considers $3 to be reasonable.
The usefulness of periodically screening asymptomatic
subjects for myocardial ischemia while on the transplant
waiting list to reduce the risk of MACE is uncertain (Class IIb;
Level of Evidence: C).
2007 Lisbon
Conference (92)
Noninvasive and/or invasive testing should be considered in
highest risk patients with the following conditions:
diabetes, prior CV disease, and multiple cardiac risk factors,
e.g., >1 yr on dialysis, LV hypertrophy, age >60 yrs,
smoking, hypertension, and dyslipidemia.
Does not specify the number of risk factors to justify testing.
2005 NKF/KDOQI
Guidelines (91)
Noninvasive stress testing recommended for all patients with
diabetes; repeat every 12 months; prior CAD if not
revascularized, repeat every 12 months; if prior PCI, repeat
every 12 months; if prior CABG, repeat after ﬁrst 3 yrs and
then every 12 months.
Repeat testing every 24 months in “high-risk” nondiabetic
patients, deﬁned as $2 traditional risk factors, known
history of CAD, LVEF #40%, peripheral vascular disease.
2001 AST Guidelines (93) Noninvasive stress testing recommended for patients at
“high risk,” deﬁned as renal disease from diabetes, history
of ischemic heart disease, or $2 risk factors.
Coronary angiography for possible revascularization before
transplantation recommended for patients with a positive
stress test result.
Revascularization before transplantation recommended for
patients with critical coronary lesions.
2000 European Best
Practice Guidelines (95)
Thallium scanning recommended for patients with history
of MI or “high-risk” clinical features.
Coronary angiography recommended if thallium scanning is
positive; revascularization advised if lesions are suitable.
ACC/AHA ¼ American College of Cardiology/American Heart Association; AST ¼ American Society of Trans-
plantation; CABG ¼ coronary artery bypass grafting; CAD ¼ coronary artery disease; CV ¼ cardiovascular; LV ¼
left ventricular; LVEF ¼ left ventricular ejection fraction; MACE ¼ major adverse cardiac events; MI ¼ myocardial
infarction; NKF/KDOQI ¼ National Kidney Foundation/Kidney Disease Outcomes Quality Initiative; PCI ¼ percu-
taneous coronary intervention.
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comes Quality Initiative Guidelines recommend
repeat stress testing every year for diabetic patients
with ESRD and every 2 years for high-risk, nondia-
betic patients (91). As shown in patients with CKD
(25–27,70,77–85,87), a normal CAD screening test
result in patients with ESRD does not carry the same
good prognosis as it does for the general population.
A >1% annual cardiac event rate is generally seen in
the presence of normal MPS, DSE, or even coronary
angiography ﬁndings (28–33,38,96). Non–CAD-related
cardiovascular complications and noncardiac comor-
bidities that are frequently present in these patients
could account partially for the “short warranty
period.” Adding anatomic information of coronary
atherosclerotic plaque burden (e.g., CACS) to thefunctional information of myocardial ischemia/scar
(MPS or DES) holds the potential to offer a more
reﬁned temporal risk discrimination. Stress imaging
is more suited for short-term risk assessment because
it detects more advanced and severe CAD. Mean-
while, CACS is a better longer-term predictor because
it can detect an earlier stage of coronary atheroscle-
rosis before the development of ﬂow-limiting
obstruction (56).
SUMMARY AND RECOMMENDATION
It is well established that patients with ESRD are a
very high-risk group for CAD and often do not have
a typical presentation of myocardial ischemia.
Although strategies incorporating clinical and stress
imaging information have been used with an overall
good degree of accuracy to detect CAD and risk-
stratify these patients, multiple challenges remain
regarding CAD screening in the asymptomatic patient
with ESRD.
It seems reasonable to be more aggressive in
screening transplant candidates for CAD considering
the surgical risk and the need to ensure the best use
of a limited organ supply. As opposed to the pre-
transplant population, no formal guidelines exist
for screening and risk stratiﬁcation in patients on
dialysis who are not being considered for transplant.
The wide array of screening tools and lack of ran-
domized trial data make clinical decision-making
challenging. Furthermore, a high-risk cohort and
accurate testing modalities do not automatically
justify routine and/or early aggressive screening
as evidenced by lessons learned from the DIAD
(Detection of Ischemia in Asymptomatic Diabetes)
study (97). The hypothesis of identifying and
treating high-risk patients with ESRD could lead
to improved survival, and the cost-effectiveness
needs to be rigorously studied in randomized trials.
The realistic expectation of screening and risk
stratiﬁcation that could have a meaningful impact on
patient outcomes would be to identify patients at
high risk for coronary events and cardiac death. In
addition to intensive risk factor modiﬁcation, the
next step would be to identify those with severe and
extensive ﬂow-limiting CAD (left main or 3-vessel
disease), whereby revascularization has the poten-
tial to improve outcomes as suggested by some
observational data (98) and a small randomized trial
involving 26 patients more than 2 decades ago (69).
Therefore, we propose that patients with ESRD with
high clinical risk (patients with diabetes, known
vascular disease, biomarker evidence of subclinical
myocardial injury, or LV dysfunction) and patients
FIGURE 4 Proposed Algorithm for CAD Screening and Risk Stratiﬁcation in Asymptomatic Patients With ESRD
CACS ¼ coronary artery calcium score; CAD ¼ coronary artery disease; CTA ¼ computed tomography angiography; CV ¼ cardiovascular;
DM ¼ diabetes mellitus; ESRD ¼ end-stage renal disease; LM ¼ left main coronary artery; LV ¼ left ventricular.
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725without high clinical risk but with a high burden of
coronary calcium could best beneﬁt from further
risk reﬁnement with stress imaging modalities of
choice. Patients who have high-risk stress ﬁndings
should be further assessed with coronary angiog-
raphy and treated accordingly (Fig. 4). Patients
with high clinical risks or non-zero CACS who have
mildly abnormal or equivocal ﬁndings could be
further assessed with coronary CTA to exclude the
presence of severe diseases (left main or multiple-
vessel disease) because their condition could be
underestimated by noninvasive imaging. The issue of
repeat testing is relevant in patients with ESRD in view
of a shorter “warranty period” after a normal stress test
result and increasing risk with longer duration of
dialysis therapy. Thus, there is a great need for inno-
vative strategies, such as hybrid imaging to reﬁne
temporal risk prediction, and vigilant monitoring of
these patients for any symptom.
BEYOND CAD SCREENING
Screening and risk stratiﬁcation for CAD are important
but only partial components in improving the overall
cardiovascular outcomes of patients with ESRD. In
addition to CAD, the presence and severity of LVH,
LV dilation, and dysfunction are also independent
predictors of cardiovascular death in these patients
(99). More than 70% of patients with ESRD have
ECG or echocardiographic evidence of LVH (100) inresponse to chronic hypertension and ﬂuid overload,
anemia, oxidative stress, and hyperparathyroidism
(101). Moreover, LVH regression or progression after
treatment of these risk factors is predictive of
cardiovascular event outcomes (102,103). Therefore,
early detection of both CAD and LVH in conjunction
with aggressive risk factor modiﬁcation should be
part of the integral management for patients with
ESRD.
In addition, sudden cardiac death due to non-
ischemic causes, such as uremic cardiomyopathy,
vascular inﬂammation, and arrhythmic risk related to
LV systolic dysfunction and electrolyte shifts, is un-
fortunately part and parcel of ESRD/dialysis and
cannot be reversed even with successful coronary
revascularization unless transplantation has been
undertaken.
Finally, limited evidence is available on the
appropriate management of heart disease in patients
with ESRD because virtually all randomized clinical
trials have excluded patients with ESRD. Therefore,
well-designed clinical studies to provide guidance for
both the risk stratiﬁcation and the management of the
growing number of these high-risk patients are ur-
gently needed.
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